SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 9.99% Stake in Evaxion Biotech A/S

Armistice Capital, LLC and Steven Boyd have disclosed a beneficial ownership of 9.99% in Evaxion Biotech A/S, holding 639,329 American Depositary Shares as of December 31, 2024.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the "Reporting Persons," have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Evaxion Biotech A/S.
• As of December 31, 2024, the Reporting Persons beneficially own an aggregate of 639,329 American Depositary Shares (ADS) of Evaxion Biotech A/S.
• This ownership represents 9.99% of the total class of American Depositary Shares.
• Armistice Capital, LLC, based in Delaware, acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC.
• Both Armistice Capital and Steven Boyd share voting and dispositive power over all 639,329 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain subjective language or performance data that would indicate a strong positive or negative sentiment. The disclosure of a significant stake by an institutional investor is generally neutral to slightly positive as it indicates investor interest.

Positives

• A significant institutional investor, Armistice Capital, and its managing member, Steven Boyd, have taken a substantial 9.99% stake in Evaxion Biotech A/S, indicating confidence in the company.
• The filing is a passive investment, suggesting a long-term view rather than an activist intent to influence control.

Future Outlook

NA

Industry Context

Evaxion Biotech A/S operates in the biotechnology sector, focusing on areas relevant to its American Depositary Shares. The disclosure of a significant stake by an investment firm like Armistice Capital can be seen as a vote of confidence in the biotech industry or the specific prospects of Evaxion Biotech A/S.

Related Party Transactions

• Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., which directly holds the shares. This relationship defines how the shares are managed and controlled.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake (9.99%) by Armistice Capital and Steven Boyd provides transparency regarding the company's ownership structure and may influence investor perception and trading activity.

Key Dates

Keywords

Evaxion Biotech A/S, Armistice Capital, Steven Boyd, Schedule 13G, SEC filing, Beneficial ownership, American Depositary Shares, Investment management, Biotechnology, Institutional investor